With more than six months to go in the year, the number of refunds that drug manufacturers have had to provide to 340B providers has already topped the previous annual record of 17. Drug manufacturer Novo Nordisk becomes the 21st manufacturer to post a notice on the U.S. Health Resources and Services Administration (HRSA) website.
Novo Nordisk, which is based in Denmark, says in its notice that it is providing 340B covered entities refunds for overcharges on six NDCs during Q3 2019 “due to revisions made to its Medicaid pricing data.” The refunds are for purchases of Saxenda (for child obesity), Fiasp (insulin), and Ozempic and Victoza (non-insulin antidiabetics).
With more than six months to go in the year, the number of refunds that drug manufacturers have had to provide to 340B providers has already topped the previous annual record of 17. Drug manufacturer Novo Nordisk becomes the 21st manufacturer to post a notice on the U.S. Health Resources and Services Administration website.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
